News and Announcements
Improving ESG with Sustainable Investment
- Published November 24, 2021 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Opportunity
Propio, the award winning UK Fintech has successfully raised £15m to create development finance loans from investor lenders to help build over 59 homes across many projects without any capital loss.
With a proven track record, Propio has relaunched the opportunity to become an investor and be part of the ESG improvement journey by funding the construction of new homes and solving the UK’s housing crisis.
As part of their continued appeal for investors, their CEO Ray Christopher generated much interest from potential investors after attending the Institute of Directors, London networking event themed ‘East meets West’. Positive reaction from Asia and around the globe demonstrates the credibility and sustainable investment opportunity up for grabs.
Propio CEO Ray Christopher shares his thoughts:
“ESG driven impact investment is rising exponentially across the globe with the Asian region growing fastest as asset managers reallocate funds. We were really pleased on the night to witness an extremely high level of engagement and interest in our ESG offering and tremendous enthusiasm for our property-backed investment opportunities in the UK.“
About the Propio Share Capital Investment opportunity:
The home of socially responsible property investing Award-winning – enabling global investors easy access to UK property-backed investment opportunities.
- Our focus – building the home of socially responsible property investing by balancing performance with purpose.
- We know – ESG investors expect a social return on investment which Propio can help end-borrowers deliver – enhancing Propio’s investor (lender) and borrower proposition, allowing Propio to provide cheaper finance than the competition – whilst enhancing margins and growing market share.
- Problem-solving – Propio solves the problems of poor market visibility/access and ESG investing for High Net Worth investors. We match SME developers with investors looking for risk-adjusted yield.
Company Updates
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Backed By Leading Investment Groups and Family Offices
